BiondVax Announces Upcoming Expiration of Public Warrants Jerusalem, Israel

Announces Upcoming Expiration of Public Warrants

Jerusalem, Israel - May 4, 2020 -

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal influenza vaccine candidate M-001, today published

a reminder that its publicly traded warrants (traded on Nasdaq under the symbol BVXVW) will expire, according to their terms, on

May 15, 2020. Warrants issued to underwriters in connection with our initial public offering in the United States will expire on

As previously announced by the Company,

holders of warrants may exercise their warrants on a cash or cashless exercise basis.

In order to exercise the warrants, brokers

must deliver, on or before 5:00 PM (ET) on May 15, 2020 (or May 11, 2020 for holders of warrants issued to underwriters), the completed

Warrant Exercise Form to the Company's transfer agent, Computershare. For warrants being exercised on a cash basis, holders must

also deliver payment of the exercise price of $6.25 per ADS for the number of public warrants being exercised plus applicable issuance

fees. For warrants being exercised on a cashless basis, holders must note on the Warrant Exercise Form that the warrants are being

exercised on a cashless basis and deliver payment of applicable issuance fees.

For additional information and copies of the exercise forms,

Voluntary Corporate Actions

150 Royall Street, Suite V

BiondVax (NASDAQ: BVXV) is a Phase 3 clinical

stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide

multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. BiondVax's proprietary

technology utilizes a unique combination of conserved and common influenza virus peptides intended to stimulate both arms of the

immune system for a cross-protecting and long-lasting effect. In a total of 7 completed Phase 1/2 and Phase 2 clinical trials enrolling

818 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. The ongoing pivotal Phase 3 clinical

trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity. For more information, please visit

Joshua E. Phillipson | +972 8 930

2529 | j.phillipson@biondvax.com

Forward Looking Statements

press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as

"expect," "believe," "intend," "plan," "continue," "may,"

"will," "anticipate," and similar expressions are intended to identify forward-looking statements. These

forward-looking statements reflect the management's current views with respect to certain current and future events and are

subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by

the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, risks relating to the

COVID-19 (coronavirus) pandemic, including a risk of delay in the availability of the top line results from our pivotal clinical

efficacy Phase 3 trial for M-001, the prosecution, timing and results of the ongoing Phase 2 and Phase 3 trials and any subsequent

trials; timing of receipt of regulatory approval of our manufacturing facility in Jerusalem; ability to demonstrate the efficacy

and safety of the vaccine; the timing of clinical trials and marketing approvals; the risk that drug development involves a lengthy

and expensive process with uncertain outcome; the ability of the Company to maintain, preserve and defend its intellectual property

and patents granted; whether our vaccine candidate will successfully advance through the clinical trial process on a timely basis,

or at all, and receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; the adequacy

of available cash resources and the ability to raise additional capital when needed. More detailed information about the risks

and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on Form

20-F for the year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on

the SEC's website, www.sec.gov. We undertake no obligation to revise or update any forward-looking statement for any reason.